文献速递治疗药物监测与药物基因组学特殊人群用药

舍曲林血药浓度在妊娠期和产后的变化

Changes in Sertraline Plasma Concentrations Across Pregnancy and Postpartum.
PubMed 文献 · Clin Pharmacol Ther · 2022-10-06

本研究为前瞻性观察队列,纳入47例接受舍曲林维持治疗的妊娠期重性抑郁障碍患者,发现妊娠晚期舍曲林浓度剂量比(C/D)较产后8周低22%,且CYP2C19慢代谢或中间代谢者C/D下降51%。

要点

  • 妊娠晚期舍曲林C/D比值较产后8周低22%,提示妊娠期清除增加。
  • CYP2C19慢代谢或中间代谢者妊娠期C/D下降51%,亚治疗浓度风险高。
  • 妊娠期应关注舍曲林浓度变化,必要时进行治疗药物监测。

核心结论

  • 妊娠期舍曲林清除增加,尤其CYP2C19慢代谢或中间代谢者C/D比值显著下降,亚治疗浓度风险高。

研究设计与样本

  • 前瞻性观察队列研究,纳入47例单胎妊娠≤18周、终生重性抑郁障碍诊断并接受舍曲林维持治疗者,来自3个NICHD资助的产科-胎儿药理学研究中心。

主要发现

  • 妊娠最后4周平均舍曲林C/D比值(95%CI)为0.25(0.19,0.3)ng/mL/dose(mg/day),产后≥8周为0.32(0.27,0.37)ng/mL/dose(mg/day),差异22%。
  • 舍曲林/去甲基舍曲林比值产后最高,证实妊娠期舍曲林消除增加。
  • CYP2C19功能正常者妊娠期C/D比值无显著变化,而慢代谢或中间代谢者C/D比值下降51%。

临床怎么用

  • 对妊娠期使用舍曲林者,尤其CYP2C19慢代谢或中间代谢者,可考虑监测血药浓度以及时发现亚治疗浓度。

局限性

  • 探索性药物基因组学分析提示CYP2C19慢代谢或中间代谢者妊娠期亚治疗浓度风险,需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Major depressive disorder (MDD) is a common disorder in pregnancy. Although sertraline is the most frequently prescribed antidepressant for pregnant people in the United States, limited information about its pharmacokinetics in pregnancy is available. Our objectives were to characterize plasma sertraline concentration to dose (C/D) ratios across pregnancy and postpartum and investigate the effect of pharmacogenetic variability on sertraline elimination. We performed a prospective observational cohort study in people with a singleton pregnancy ≤ 18 weeks gestation and a lifetime diagnosis of MDD at the 3 Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)-funded Obstetrical-Fetal Pharmacology Research Center sites. Subjects (N = 47) were receiving maintenance sertraline therapy and chose to continue it during pregnancy. Blood samples were obtained 24-hours postdose every 4 weeks across pregnancy and twice postpartum for measurement of plasma concentrations of sertraline and desmethylsertraline. Overall mean sertraline C/D ratios were decreased at study onset and remained consistently low until after delivery. During the last 4 weeks of pregnancy the mean sertraline C/D ratio (95% confidence interval (CI)), 0.25 (95% CI, 0.19, 0.3) ng/mL/dose (mg/day), was smaller than the mean ratio at ≥ 8 weeks after delivery, 0.32 (95% CI, 0.27, 0.37) ng/mL/dose (mg/day), a 22% difference. Mean sertraline/desmethylsertraline ratios were highest after birth, which confirmed increased sertraline elimination during pregnancy. Sertraline C/D ratios in participants with functional CYP2C19 activity did not change significantly during pregnancy, whereas ratios in participants with poor or intermediate CYP2C19 activity decreased by 51%. Exploratory pharmacogenomic analysis indicated that pregnant people with poor or intermediate CYP2C19 activity are at risk for subtherapeutic sertraline concentrations during pregnancy.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Stika CS, Wisner KL, George AL, et al. Changes in Sertraline Plasma Concentrations Across Pregnancy and Postpartum. Clin Pharmacol Ther. 2022. PMID: 36094046. doi:10.1002/cpt.2746

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。